



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
FOURTH QUARTER OF 2021 (2021Q4)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**

This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.



Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites.
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.




Reports for 2020 Q2 and after reflect a changed definition of medication assisted treatment (MAT). The older definition defined MAT as buprenorphine/naloxone combination products only. The new definition has been applied to all quarters included in this report and includes all buprenorphine products except a couple of types indicated for the treatment of pain. Because MAT products are usually high-dose prescriptions and are counted separately from other opioids, this change has an effect on many of the indicators in this report.

Prior to 2020 Q4, a number of controlled substances were excluded from the analyses that are the basis of this report. These included the barbiturates and some miscellaneous controlled substances (notably testosterone and pregabalin). The inclusion of these drugs increased the number of controlled substance patients and providers reported, and increased the number of patients with multiple providers or pharmacies. Most other indicators were not affected.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
Total number of controlled substance patients	215,976	220,969	216,679	-1.9%	0.3%
Number of patients receiving opioids (excluding MAT)	119,838	117,173	114,325	-2.4%	-4.6%
Number of opioid prescriptions filled (excluding MAT)	261,432	248,966	242,343	-2.7%	-7.3%
Number of MAT buprenorphine prescriptions filled	29,331	27,882	28,033	0.5%	-4.4%
Number of high dose (≥ 90 MME/day) opioid prescriptions (excluding MAT)	24,483	21,507	21,056	-2.1%	-14.0%
Total MME of opioids filled - (excluding MAT)	199,446,726	180,384,507	175,622,906	-2.6%	-11.9%
Total MME/prescription-day	47	45	44	-1.1%	-5.3%
Number of patients receiving benzodiazepines	73,636	70,211	68,125	-3.0%	-7.5%
Number of benzodiazepine prescriptions filled	163,448	152,796	147,829	-3.3%	-9.6%
Number of high-dose(≥ 40 DME/day) benzodiazepine prescriptions filled	27,251	23,908	23,118	-3.3%	-15.2%
Total DME of benzodiazepines filled	81,431,360	73,613,949	71,404,884	-3.0%	-12.3%
Total DME/patient	1,106	1,048	1,048	0.0%	-5.2%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MAT = Medication assisted treatment - the use of buprenorphine products indicated for treatment of opioid use disorder. Excludes products indicated for the treatment of pain.

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
High dose opioids (>=90 MME/day) (excluding MAT)	8,797	7,893	7,831	-0.8%	-11.0%
High dose benzodiazepines (>=40 DME/day)	11,898	10,487	10,140	-3.3%	-14.8%
Opioids >=90 days and <90% of days in past 6 months (excluding MAT)	14,625	14,279	14,228	-0.4%	-2.7%
Opioids >=90% of days in past 6 months (excluding MAT)	28,110	26,158	25,520	-2.4%	-9.2%
Benzodiazepines >=90 days and <90% of days in past 6 months	17,720	16,604	16,431	-1.0%	-7.3%
Benzodiazepines >=90% of days in past 6 months	22,378	21,116	20,453	-3.1%	-8.6%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	1,957	1,969	1,940	-1.5%	-0.9%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	1,430	1,358	1,304	-4.0%	-8.8%
Concurrent opioid and benzodiazepines (>=10 days overlap)	13,076	11,814	11,612	-1.7%	-11.2%
High dose opioids (>=90 MME/day) plus benzodiazepines	1,996	1,740	1,677	-3.6%	-16.0%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	1,613	1,544	1,540	-0.3%	-4.5%
New Opioid Patients with at least 30 days of coverage in the past 3 months (excl MAT)	2,067	2,002	2,103	5.0%	1.7%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	3,273	2,986	3,047	2.0%	-6.9%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
Total active controlled substance prescribers	2,972	3,081	3,038	-1.4%	2.2%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	34	27	23	-14.8%	-32.4%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	112	110	87	-20.9%	-22.3%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	5	2	2	0.0%	-60.0%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,713	1,819	1,846	1.5%	7.8%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	238	245	211	-13.9%	-11.3%
Number of Patients with PMP reports requested by practitioners	343,904	402,977	400,459	-0.6%	16.4%
% of Chronic opioid users with a PMP request in the past 3 months*	82.3%	83.0%	82.8%	-0.3%	0.6%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	60.5%	60.5%	60.9%	0.7%	0.7%
% of New Opioid Patients with a PMP request in the past 3 months**	40.0%	46.1%	46.9%	1.7%	17.2%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	44.4%	47.5%	48.6%	2.3%	9.4%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (buprenorphine and methadone) Measures

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
Buprenorphine MAT prescribers with at least 10 treatment patients	227	239	236	-1.3%	4.0%
Buprenorphine MAT patients (>=10 days)	8,154	8,083	8,241	2.0%	1.1%
Buprenorphine MAT prescriptions filled	29,331	27,882	28,033	0.5%	-4.4%
Total Practitioners with DATA Waiver	1,118	1,249	1,319	5.6%	18.0%
Nurse Practitioners and PAs with DATA Waiver	378	455	483	6.2%	27.8%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	5,973	6,205	6,241	0.6%	4.5%
Number of distinct NM Medicaid providers of methadone	11	14	13	-7.1%	18.2%

Methadone Treatment Programs by Survey Date	Dec 2020	Oct 2021	Dec 2021		
Number of Methadone Treatment Programs	19	20	21	5.0%	10.5%
Number of Methadone Treatment Patients in those Programs	6,078	7,277	7,335	0.8%	20.7%


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine MAT data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
New Enrollments in NM State Government Naloxone Programs	1,879	2,345	3,468	47.9%	84.6%
Total Number of NM Naloxone Doses distributed*	8,070	14,136	17,310	22.5%	114.5%
Total Number of NM Reported Reversals**	698	1,009	935	-7.3%	34.0%

Year and Quarter	2020Q4	2021Q3	2021Q4	Quarterly % Change 2021Q3 vs 2021Q4	Quarterly % Change 2020Q4 vs 2021Q4
Pharmacies Presenting Medicaid Naloxone Claims+	251	251	246	-2.0%	-2.0%
Number of Medicaid Naloxone Claims Processed	4,235	5,042	3,618	-28.2%	-14.6%

*Some naloxone doses were given to organizations and may not have been distributed in that quarter.

**Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

+An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 286 outpatient Pharmacies with a NM address in 2019 according to the Board of Pharmacy.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

